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Pengfei Li1,2†, Li Jiang1,2†, Xinke Zhang1,3, Jun Liu1,3 and Hua Wang1,2,4*Abstract
Background: Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), is an aggressive type of lymphoma whose
standard treatment and validated prognostic model have not yet been defined.
Methods: CD30 expression was detected using immunohistochemistry in 96 ENKTL patients, and the data were used
to evaluate its relationship with clinical features, treatment response and prognosis.
Results: Expression of CD30 was detected in 31.2% of ENKTL patients, which was significantly correlated with B
symptoms and elevated serum lactate dehydrogenase. The complete remission rate was not significantly different
between CD30-positive and negative groups. After a median follow-up time of 31 months, 5-year overall survival
(OS) and 5-year progression-free survival (PFS) rates in the CD30-positive group were both significantly lower than
those in the CD30-negative group (34.1% vs. 64.4%, P = 0.002, for 5 year-OS; 26.0% vs. 66.7%, P < 0.001, for 5 year-PFS).
In patients with an International Prognostic Index (IPI) or Korean Prognostic Index (KPI) score of 0–1, CD30 positivity
was associated with shorter 5-year OS and PFS (IPI: P = 0.001 and 0.002, respectively; KPI: P = 0.018 and 0.023,
respectively). In a multivariate Cox regression model, CD30 expression and stage were independent prognostic
factors for OS (p = 0.004 and p = 0.012, respectively) and PFS (p = 0.001 and p = 0.022, respectively).
Conclusions: Our results showed that expression of CD30 was not related to response to treatment but was
an independent prognostic factor for both OS and PFS in ENKTL, nasal type, which suggests a role for CD30 in
the pathogenesis of this disease and may support the incorporation of anti-CD30-targeted therapy into the
treatment paradigm for ENKTL.
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PrognosisBackground
Extranodal natural killer (NK)/T-cell lymphoma (ENKTL),
nasal type, is a distinct and heterogeneous histopathologic
subtype of non-Hodgkin lymphoma (NHL) characterized
by vascular damage and destruction, prominent necrosis
and association with the Epstein-Barr virus (EBV) [1,2].
There is an ethnic and geographical predisposition to
ENKTL. Though uncommon in Western countries,* Correspondence: wanghua@sysucc.org.cn
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unless otherwise stated.ENKTL is relatively more common in Asia and Latin
America [3,4] and accounts for 5–10% of all malignant
lymphomas in China. Owing to its poor prognosis, a
great deal of clinical and pathological work has been
undertaken to study prognostic markers in ENKTL.
Clinically, two major prognostic models have been ap-
plied to study NK/T-cell lymphomas: the International
Prognostic Index (IPI; age, PS, stage, lactate dehydrogenase
(LDH) level and extranodal sites) and the Korean Prog-
nostic Index (KPI: stage, LDH level, B symptoms and
regional lymph nodes). IPI has been widely used for both
predicting prognosis and selecting therapeutic options in
patients with aggressive NHL. However, its value has not
been confirmed in ENKTL because almost 80% of patientsis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Li et al. BMC Cancer 2014, 14:890 Page 2 of 8
http://www.biomedcentral.com/1471-2407/14/890with ENKTL were in the low IPI risk group (score 0–1), in
which a good deal of heterogeneity exists. The KPI was
developed in the era of anthracycline-based chemotherapy,
which seems better than the IPI [5,6]. However, the prog-
nostic value of KPI could not be repeated in some studies,
especially in the era of asparaginase-based chemotherapy
[7], suggesting that both IPI and KPI scoring systems
could be further improved. Moreover, the two prognos-
tic models are based on clinical features before treatment;
the pathological or molecular markers for predicting
the outcome of ENKTL have not yet been well defined.
Recently, some useful biomarkers have been found to
be independent prognostic factors in ENKTL [8], such
as serum levels of interleukin-9 [9] and serum C-reactive
protein [10].
Recently, there have been some sporadic comparisons
of the CD30 cDNA with known sequences indicating that
the extracellular domain of CD30 is related to members of
the tumor necrosis factor receptor (TNFR) superfam-
ily, which includes TNFR-1, TNFR-2 and low-affinity
nerve growth factor receptor [11]. The recently cloned
membrane-bound CD30 ligand (CD30L) belongs to the
TNF ligand superfamily and confirms that CD30 might
act as a cytokine receptor [12]. Functional studies using
recombinant CD30L showed proliferative effects on some
HD-derived cell lines and a T-All cell line [13]. There
are some scattered reports regarding CD30 expression
in ENKTL patients. Moreover, the clinical significance
of CD30 expression for predicting prognosis in ENKTL
has been unclear. Here, we measured CD30 expression
to evaluate its prognostic value in ENKTL.
Methods
Patients
Ninety-six patients were selected with pathologically proven
ENKTL diagnosed from August 2000–June 2013 at the
Sun Yat-Sen University Cancer Center. Histology, immu-
nophenotype and EBV status were reviewed to confirm the
diagnosis based on World Health Organization guidelines
[14]. The criteria for case inclusion were as follows: (1)
histologically confirmed diagnosis of ENKTL; (2) NK/
T-cell type proven using immunohistochemistry (IHC),
flow cytometry or EBV in situ hybridization; (3) no previ-
ous malignancy; (4) no previous treatment for lymphoma;
and (5) adequate clinical information and follow-up data.
Moreover, patients with aggressive NK cell lymphoma/
leukemia, peripheral T-cell lymphoma, blastic NK cell
lymphoma/leukemia or negative EBV in situ hybridization
were excluded from the analysis. The clinical data con-
tained the following information: patient demographics,
physical examinations, Eastern Cooperative Oncology
Group performance status (ECOG PS), B symptoms,
primary site, involved sites, serum β2 microglobulin
(β2 M), serum LDH, bone marrow examination, endoscopicexamination of the nasal and oral cavity, computed
tomography (CT) or magnetic resonance imaging (MRI)
of the involved field or whole body positron emission
tomography/computed tomography (PET/CT). All patients
were staged according to the Ann Arbor staging system, as
calculated using the IPI and KPI.
The primary tumor site was classified into two subtypes:
upper aerodigestive tract NK/T-cell lymphoma (UNKTL;
primary tumors confined to the nasal cavity, nasopharynx,
paranasal sinuses, tonsils, hypopharynx and larynx) and
extra-UENKTL (EUNKTL; primary tumors at all other
sites in the absence of nasal disease) [7,15]. Primary tu-
mors within the nasal cavity and secondary spread to other
organs were regarded as UNKTL. Both the Institutional
Review Board and Ethics Committees of Sun Yat-Sen
University Cancer Center approved the study. All patients
consented to the use of their medical records for research
purposes.
Treatment and response evaluation
Patient treatment strategies were as follows: (1) chemo-
therapy alone; or (2) chemotherapy followed by involved
field radiotherapy (IFRT). The chemotherapy regimens
were: (1) EPOCH (etoposide, doxorubicin, vincristine,
cyclophosphamide and prednisone); or (2) GELOX
(gemcitabine, oxaliplatin and L-asparaginase) or modified
GELOX [16]. Patients received at two to six cycles of ini-
tial chemotherapy. The IFRT of 36–60 Gy was delivered
in daily fractions of 1.8–2.0 Gy (five fractions each week).
Treatment response was assessed according to the Inter-
national Working Group Recommendations for Response
Criteria for NHL [17,18]. Routine follow-up imaging ana-
lyses were performed every 3 months for the first 2 years,
every 6 months for the next 3 years and yearly thereafter,
or whenever clinically indicated.
IHC for CD30
Representative formalin-fixed, paraffin-embedded tissues
obtained from surgical resections or biopsies were
submitted for IHC. Four-micrometer-thick sections of
paraffin-embedded tissues were cut, placed on slides,
deparaffinized in xylene and hydrated in a graded alcohol
series. Immunohistochemical staining of CD30 was per-
formed on selected cases using a CD30 antibody (Invitrogen,
Carlsbad, CA, USA) incubated at a 1:50 dilution. IHC was
performed using a modified avidin-biotin peroxidase
complex amplification and detection system. Specimens
were analyzed according to the local ethical guidelines
and approved study protocols. The percentage of CD30
expression was quantified by determining the amount of
positive cells with membrane staining among the total
number of tumor cells in the high-power field under
high magnification (×400). A semi-quantitative scoring
system for CD30 expression was applied using the
Table 1 Clinical characteristics of patients at diagnosis
Characteristics Presence Presence %
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cells stained; (2) “positive”, 10–50% of tumor cells stained;
(3) “strongly positive”, more than 50% of tumor cells with
clearly stained cell membranes. Two pathologists (Liu and
Zhang) performed all analyses in a single laboratory. The
pathologist who performed the cell counts was blinded to
the clinical characteristics and survival status.Male 61 63.5
Female 35 36.5
ECOG PS






Mass long diameter ≥5 cm 36 37.5
Local tumor invasion 61 63.5
Extranodal sites ≥2 57 59.4
Regional lymphadenopathy 51 53.1
Elevated serum LDH 41 42.7
Elevated serum β2 M* 40 67.8
Ann Arbor stageStatistical analysis
Overall survival (OS) was determined from the date of
diagnosis to the date of death or the last follow-up visit.
Progression-free survival (PFS) was measured from the
date of diagnosis to the date of disease progression, re-
lapse, death or the date of the last follow-up visit. The
relationship of CD30 expression with clinical variables
was calculated using the chi-squared test or Fisher’s exact
test. The Kaplan-Meier method was used to calculate OS
and PFS, and survival curves were compared using the
log-rank test. The Cox proportional hazards regression
model was used for the multivariate analysis to compare
factors proven statistically significant in the univariate
analysis. A two-sided p-value of less than 0.05 was consid-
ered statistically significant. All analyses were performed
using SPSS software (SPSS Standard version 19.0, SPSS,
Chicago, IL, USA).I, II 71 74.0
III, IV 25 26.0
IPI score
0, 1 58 60.4
≥2 38 39.6
KPI score








The main clinical characteristics of the 96 patients are
presented in Table 1. The median age was 41 years and
ranged from 17 to 89 years. The ratio of males to females
was 2:1. Eighty-eight patients (91.7%) had good a ECOG
PS of 0–1. The majority of patients initially presented with
UNKTL tumors (n = 63, 65.6%) or localized disease (stages
I and II; n = 71, 74%). In patients with EUNKTL, primary
lesion sites involved the small bowel, colon, lung, skin,
testis and soft tissues. Over half of the patients were classi-
fied into the low-risk group according to their IPI or KPI
score.Chemotherapy + radiotherapy 61 63.5
Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status,
UNKTL upper aerodigestive tract NK/T-cell lymphoma, EUNKTL extra-upper
aerodigestive tract NK/T-cell lymphoma, LDH lactate dehydrogenase,
β2 M Beta-2 microglobulin, IPI International Prognostic Index, KPI Korean
Prognostic Index.
*Serum β2 M was detected in 59 cases.Correlation between CD30 expression and clinical
features
Correlations between CD30 expression and main clin-
ical parameters are summarized in Table 2. CD30 was
expressed in 31.2% of ENKTL patients (Figure 1). We
observed no association between CD30 expression and
other clinical features such as age, gender, local tumor
invasion, extranodal sites, ECOG PS, stage, IPI and KPI
scores. The CD30-positive group showed statistically sig-
nificant increases in cases with B symptoms and elevated
serum LDH compared with the CD30-negative group
(p = 0.028 and p = 0.021, respectively).Treatment response and survival
All 96 patients received chemotherapy; 55 patients re-
ceived the EPOCH regimen whereas the other 41 patients
received the GELOX regimen. Sixty-one patients received
chemotherapy followed by IFRT whereas 35 patients re-
ceived only chemotherapy. No statistical difference was
Table 2 Clinical characteristics according to CD30-positive
versus CD30-negative expression at diagnosis
Characteristics CD30-positive CD30-negative P-value
No. of patients 30 66












B-symptoms 20 28 0.028
Mass (diameter) ≥5 cm 9 27 0.306
Local tumor invasion 21 40 0.375
Extranodal sites ≥2 20 37 0.327
Regional lymphadenopathy 17 34 0.639
Elevated serum LDH 18 23 0.021
Stage 0.684
I, II 23 48
III, IV 7 18
IPI score 0.339
0, 1 16 42
≥2 14 24
KPI score 0.057







Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance
status, UNKTL upper aerodigestive tract NK/T-cell lymphoma, EUNKTL extra-upper
aerodigestive tract NK/T-cell lymphoma, LDH lactate dehydrogenase, IPI
International Prognostic Index, KPI Korean Prognostic Index.
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CD30-positive vs. CD30-negative expression at diagnosis
(p = 0.627).
The treatment response was evaluated in each patient.
Results showed that 65 patients (67.7%) and 17 patients
(17.7%) achieved complete remission (CR) and partial re-
sponse (PR), respectively, thus the overall response rate
(ORR) was 85.4%. CR rates of patients with CD30-positiveand CD30-negative expression were 60.0% (18/30) and
71.2% (47/66), respectively (p = 0.276).
Within a median follow-up time of 31 months (5–152),
the 5-year OS and PFS rates were 53.9% (95% CI, 35.0–
69.8%) and 42.1% (95% CI, 27.6–56.6%), respectively.
Patients who were CD30-positive tended to have shorter
OS (5-year OS, 34.1% vs. 64.4%; p = 0.002) and PFS (5-year
PFS, 26.0% vs. 66.7%; p < 0.001). In patients who received
chemotherapy alone (35 cases, 36.5%), CD30-positivity
was associated with shorter OS and PFS (p = 0.037 and
p = 0.018, respectively), and in patients who received
chemotherapy followed by radiotherapy (61 cases, 63.5%),
CD30-positivity at diagnosis was also related to inferior
OS and PFS (p = 0.033 and p = 0.005, respectively). For
patients in the IPI 0–1 subgroup (58, 60.4%), CD30-
positivity was associated with shorter OS and PFS (p =
0.001 and p = 0.002, respectively). Similarly, for patients
in the KPI 0–1 subgroup (49, 51.0%), CD30-positivity
at diagnosis was also related to inferior OS and PFS
(p = 0.018 and p = 0.023, respectively).
Univariate and multivariate analysis
Univariate analysis showed that B symptoms, two or more
extranodal sites, elevated serum LDH, local tumor inva-
sion, advanced stage (III/IV) and CD30-positivity, IPI
and KPI could significantly predict shorter OS and PFS.
Age and subtype showed statistical significance with OS
(p = 0.049 and p = 0.022, respectively), but failed to show
prognostic significance for PFS. Clinical factors that were
statistically significant predictors of OS and PFS were in-
cluded in the multivariate analysis. We did not include IPI
and KPI values in the multivariate analysis because of their
overlap with several other clinical variables. Multivariate
analysis revealed that CD30 expression was an independ-
ent prognostic factor for OS (response rates (RR) = 3.345;
95% CI, 1.477–7.575; p = 0.004) and PFS (RR = 4.391; 95%
CI, 1.940–9.941; p = 0.001). The stage was also an inde-
pendent prognostic factor for OS (RR = 3.497; 95% CI,
1.314–9.346; p = 0.012) and PFS (RR = 2.841; 95% CI,
1.166–6.945; p = 0.022). However, other factors such as
B symptoms, two or more extranodal sites, elevated
serum LDH and local tumor invasion failed to be prog-
nostic for OS or PFS (Table 3).
Discussion
In this study, the expression for CD30 in ENKTL patients
was significantly correlated with B symptoms and elevated
serum LDH. Furthermore, although CD30 expression did
not appear to affect the response to GELOX or EPOCH
chemotherapy, survival analysis indicated that CD30-
positive patients had a significantly inferior OS and PFS.
According to the Cox regression model that included B
symptoms, two or more extranodal sites, elevated serum
LDH, local tumor invasion, advanced stage (III/IV) and
Figure 1 Immunohistochemical analysis of CD30 expression in extranodal natural killer T-cell lymphomas, nasal type (ENKTL). A and B,
representative images of CD30-positive tumor cells showing strong cell membrane staining (brown) (magnification in A × 100, B × 400); C and D,
representative image of CD30-negative tumor cells showing no membrane staining (magnification in C × 100, D × 400).
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was an independent prognostic factor for both OS and
PFS.
The fact that CD30 was expressed in both tumor cells
and certain activated normal lymphoreticular cells implies
that it has a general cell-growth or activation role. Hsu et al.
found a high level of CD30 and CD30L co-expression
in H-RS cells, and increased proliferation was noted uponTable 3 Results of univariate and multivariate analyses of pro
Parameter PFS
Univariate analysis Multivariate analy
P-value RR (95% CI)
Age >60 years 0.120
Gender, male 0.563
ECOG PS ≥2 0.436
Subtype, EUNKTL 0.098
B symptoms 0.001
Mass long diameter >5 cm 0.105
Local tumor invasion 0.001
Extranodal sites ≥2 0.002
Regional lymphadenopathy 0.095
Elevated serum LDH < 0.001
CD 30 positive < 0.001 4.391 (1.940–9.941)
Stage III, IV < 0.001 2.841 (1.166–6.945)
IPI score ≥2 < 0.001
KPI score ≥2 < 0.001
Abbreviations: PFS progression-free survival, OS overall survival, RR relative risk, CI c
status, EUNKTL extra-upper aerodigestive tract NK/T-cell lymphoma, LDH lactate dehtreatment with exogenous CD30L [19]. Primary cutaneous
large T-cell lymphomas, which are negative for CD30
originally and develop CD30 secondarily during the course
of the disease, present a worse clinical course and have a
poor prognosis.
In this present study, we retrospectively analyzed the
relationship between CD30 expression and clinicopatho-
logical features, and found that CD30-positive expressiongnostic factors for PFS and OS in patients with ENKTL
OS
sis Univariate analysis Multivariate analysis











0.001 0.002 3.345 (1.477–7.575) 0.004
0.022 < 0.001 3.497 (1.314–9.346) 0.012
< 0.001
< 0.001
onfidence interval, ECOG PS Eastern Cooperative Oncology Group performance




Figure 2 Overall survival (OS) and progression-free survival (PFS) according to CD30-positive vs. CD30-negative expression at diagnosis
in patients with extranodal natural killer T-cell lymphomas, nasal type (ENKTL). Kaplan-Meier plots of OS (A) for all patients and PFS (B) for
all patients; Kaplan-Meier plots of OS (C) and PFS (D) for subgroups with low International Prognostic Index (IPI) scores of 0–1; Kaplan–Meier plots
of OS (E) and PFS (F) for subgroups with low Korean Prognostic Index (KPI) scores of 0–1.
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elevated LDH levels. As discussed above, binding of CD30
and CD30L can promote proliferation of H-RS cells. This
effect may exist in ENKTL, supporting the result that in
CD30-positive ENKTL patients, LDH levels, which reflect
the speed of tumor cell proliferation, was higher than that
in CD30-negative patients. In our study, 31.2% (30/96) of
patients showed positive expression of CD30 in ENKTL
cells, which corresponded well with the result reported by
Junshik et al., in which they found that 36.4% patients
(8/22) with ENKTL showed positive expression of CD30
and the prognosis of these patients was inferior to those
with negative expression [20].
In the present study, the rates of CR and ORR were not
significantly different between the two groups after
chemotherapy or radiotherapy, but the survival analysis
indicated that the 5-year rates of OS and PFS in the
CD30-negative group were both significantly higher than
those in the CD30-positive group (64.4% vs. 34.1%, P =
0.002, for 5-year OS; 66.7% vs. 26.0%, P < 0.001, for 5-year
PFS). Furthermore, subgroup analysis showed that CD30-
negative patients had a better prognosis, regardless of
treatment modality (chemotherapy followed by IFRT or
chemotherapy alone). Our results were consistent with
the study conducted by Junshik et al. that showed that
patients with CD30 expression had an inferior OS and
PFS compared with those without CD30 expression.
Nevertheless, CD30-positive patients tended to have a
better prognosis in one study (n = 30), while in two
other studies performed by Kuo et al. (n = 22) [21] and
Gaal et al. (n = 15) [22], although it appeared that CD30
expression was related to angiodestruction, pleomorphic
cell type or thrombus formation, there were no survival
differences in terms of CD30 expression. However, in their
study, the prognostic significance of CD30 expression was
established on the basis of small sample sizes, and one of
the studies only referred to NK/T-cell lymphomas present-
ing on the skin. One other thing to note is the influence of
different CD30 cutoff levels on the final result. In our
study, CD30 expression was considered positive when
more than 10% of tumor cells showed strong mem-
brane staining. Perhaps CD30 cutoff levels, which were
different from ours (absolute values not shown in their
article), resulted in the contradictory findings mentioned
above.
As discussed above, CD30 expression had no effect on
the rate of response to treatment, but only affected the
long-term survival. The results indicated that CD30 ex-
pression in ENKTL cells only promotes cell proliferation
without affecting its sensitivity to therapy. Furthermore,
the presence of EBV appears to occur more frequently in
CD30-positive lymphomas when compared with CD30-
negative lymphomas. EBV is known for its ability to up-
regulate CD30 in EBV-positive lymphoma cell lines. Thus,it is hypothesized that CD30 may be involved in tumor cell
growth regulated by EBV in CD30-positive ENKTL and
result in a poor prognosis.
Clinically, two major clinical prognostic models are ap-
plied in NK/T-cell lymphoma: IPI and KPI. In the present
study, univariate analysis showed that the two models were
highly prognostic. Distribution of patients within risk
groups based on IPI and KPI scores is presented in Table 1.
For IPI scores, more than 70% of all cases were in the
low-risk category (with no or one adverse factor). The
KPI model showed a better balanced distribution of pa-
tients into different risk groups than the IPI model. How-
ever, these two prognostic models failed to differentiate
patients with different outcomes in the low-risk group. As
is depicted in Figure 2, CD30 expression can divide
patients with IPI or KPI scores of 0–1 into two sub-
groups with significant differences in OS and PFS (IPI:
P = 0.001 and P = 0.002, respectively; KPI: P = 0.018 and
P = 0.023, respectively). Thus, CD30 expression can be
a good independent prognostic factor for OS and PFS
not only in the entire group of ENKTL patients, but
also in those with low-risk IPI scores.
Radiation therapy is widely administered to patients
with localized nasal disease, and produces a complete re-
sponse rate of up to 70% [23]. However, local and systemic
failures were observed frequently in patients who receive
radiation therapy alone [24]. Therefore, chemotherapy is
required in combination with radiotherapy to reduce the
risk of recurrence. In the present study, some patients de-
veloped primary or secondary resistance to chemotherapy.
Thus, novel drugs or treatment regimens are urgently
needed. SGN-35, a humanized CD30 antibody coupled to
monomethyl-auristatin E, exhibited potent and specific
cytotoxicity against CD30-positive cells in vitro and in vivo
[25,26]. SGN-35 (brentuximab vedotin) was approved for
treatment in patients with relapsed Hodgkin lymphoma
and relapsed systemic anaplastic large-cell lymphoma.
As was demonstrated above, one-third of patients with
ENKTL highly expressed CD30. Thus, brentuximab
vedotin may also have an effect in ENKTL patients,
and needs to be tested in preliminary studies and clinical
trials.Conclusions
In conclusion, it was found that the expression of CD30
was an independent prognostic factor for both OS and
PFS in ENKTL, nasal type. Further investigation is re-
quired to provide a better understanding of the mecha-
nisms underlying the association between CD30 and
clinical outcome. These results need to be validated in
prospective trials and may support the incorporation of
anti-CD30-targeted therapy into current treatment strat-
egies against ENKTL.
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